Anticholinergic use for more than 3 months Increased risk of dementia

A recent literature review of the long-term use of anticholinergic drugs used to treat overactive bladder symptoms, showed an increase risk of dementia by an average of 46%. Anticholinergic drugs include oxybutynin, solifenacin, darifenacin, tolterodine and trospium. ( Neurology and urodynamics 2021;40:15-24 )

National pessary guideline March 2021

The Guideline group (which I was part of) feel this will open the door for women to learn, understand and be empowered to ask about whether a pessary is the right option for them. The full guideline can be accessed here https://www.ukcs.uk.net/UK-Pessary-Guideline-2021, The patient information section is here https://thepogp.co.uk/patient_information/womens_health/pessaries_for_prolapse.aspx

HRT

"Lenzetto" is now available in the UK.   This is an estradiol transdermal spray. The Medicines and Healthcare Products Regulatory Agency granted a marketing authorisation valid throughout the European Union for Lenzetto on 13 August 2015. Gedeon Richter UK launched Lenzetto in the UK on 1st April 2020.

Fibroids

"Esmya" the medicine used to treat fibroids, has been withdrawn because of fears over liver toxicity

Urine incontinence surgery

The use of mesh placed under the mid-urethra (Tension free Vaginal Tape),  continues to be suspended - Baroness Cumberledge has completed her report, and the RCOG are implementing the recommendations